NO20040479L - Solvater av lerkanidipinhydroklorid og nye krystallinske former av lerkanidipinhydroklorid. - Google Patents

Solvater av lerkanidipinhydroklorid og nye krystallinske former av lerkanidipinhydroklorid.

Info

Publication number
NO20040479L
NO20040479L NO20040479A NO20040479A NO20040479L NO 20040479 L NO20040479 L NO 20040479L NO 20040479 A NO20040479 A NO 20040479A NO 20040479 A NO20040479 A NO 20040479A NO 20040479 L NO20040479 L NO 20040479L
Authority
NO
Norway
Prior art keywords
lercanidipine hydrochloride
solvates
crystalline forms
new crystalline
lercanidipine
Prior art date
Application number
NO20040479A
Other languages
English (en)
Norwegian (no)
Inventor
Amedo Leonardi
Fausto Bonifacio
Gianluca De Lasi
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Publication of NO20040479L publication Critical patent/NO20040479L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20040479A 2001-08-06 2004-02-03 Solvater av lerkanidipinhydroklorid og nye krystallinske former av lerkanidipinhydroklorid. NO20040479L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI001727A ITMI20011727A1 (it) 2001-08-06 2001-08-06 Solvati della lercanidipina cloridrato e nuove forme cristalline della lercanidipina cloridrato ottenute da essi
PCT/EP2002/008700 WO2003014085A1 (en) 2001-08-06 2002-08-05 Solvates of lercanidipine hydrochloride and new crystalline forms of lercanidipine hydrochloride

Publications (1)

Publication Number Publication Date
NO20040479L true NO20040479L (no) 2004-02-03

Family

ID=11448246

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040479A NO20040479L (no) 2001-08-06 2004-02-03 Solvater av lerkanidipinhydroklorid og nye krystallinske former av lerkanidipinhydroklorid.

Country Status (21)

Country Link
EP (1) EP1423367B1 (pl)
JP (1) JP2005502648A (pl)
KR (1) KR100912664B1 (pl)
CN (1) CN100494175C (pl)
AR (1) AR037230A1 (pl)
AT (1) ATE294162T1 (pl)
AU (1) AU2002331390B2 (pl)
BR (1) BR0211738A (pl)
DE (1) DE60203919D1 (pl)
EA (1) EA200400279A1 (pl)
ES (1) ES2209684T1 (pl)
HR (1) HRP20040157A2 (pl)
HU (1) HUP0401161A3 (pl)
IL (2) IL153916A0 (pl)
IT (1) ITMI20011727A1 (pl)
MX (1) MXPA04001073A (pl)
NO (1) NO20040479L (pl)
PE (1) PE20030350A1 (pl)
PL (1) PL369449A1 (pl)
UY (1) UY27409A1 (pl)
WO (1) WO2003014085A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100651212B1 (ko) 2004-10-27 2006-12-01 제일약품주식회사 무정형 레르카니디핀의 제조방법
AR052918A1 (es) 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
EP1940790B1 (en) * 2005-09-16 2015-09-02 Glenmark Pharmaceuticals Limited Polymorphic form of lercanidipine hydrochloride and process for the preparation thereof
CN101868442A (zh) * 2007-03-05 2010-10-20 阿克塔维什集团Ptc公司 盐酸乐卡地平多晶型物和1,1,n-三甲基-n-(3,3-二苯基丙基)-2-氨基乙酰醋酸乙酯的改进制法
WO2008136394A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. ラクタム化合物の製造方法及びその製造中間体
WO2011161223A2 (en) 2010-06-23 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts
SI2654729T1 (sl) 2010-12-24 2016-08-31 Krka, D.D., Novo Mesto Homogene farmacevtske oralne dozirne oblike, ki obsegajo lerkanidipin in enalapril ali njune farmacevtsko sprejemljive soli skupaj z organsko kislino

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403866D0 (en) * 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
US5767136A (en) * 1995-05-12 1998-06-16 Recordati, S.A. Chemical And Pharmaceutical Company 1,4-Dihydropyridines useful for prevention or reduction of atherosclerotic lesions on arterial walls

Also Published As

Publication number Publication date
HUP0401161A2 (hu) 2004-09-28
ITMI20011727A0 (it) 2001-08-06
CN1538958A (zh) 2004-10-20
IL153916A (en) 2008-07-08
EA200400279A1 (ru) 2004-06-24
UY27409A1 (es) 2003-03-31
IL153916A0 (en) 2003-07-31
BR0211738A (pt) 2004-09-28
ITMI20011727A1 (it) 2003-02-06
JP2005502648A (ja) 2005-01-27
WO2003014085A1 (en) 2003-02-20
HUP0401161A3 (en) 2009-04-28
CN100494175C (zh) 2009-06-03
AU2002331390B2 (en) 2008-06-05
DE60203919D1 (de) 2005-06-02
MXPA04001073A (es) 2005-02-17
ATE294162T1 (de) 2005-05-15
PE20030350A1 (es) 2003-06-06
EP1423367B1 (en) 2005-04-27
KR20040030932A (ko) 2004-04-09
KR100912664B1 (ko) 2009-08-17
HRP20040157A2 (en) 2004-08-31
ES2209684T1 (es) 2004-07-01
PL369449A1 (pl) 2005-04-18
EP1423367A1 (en) 2004-06-02
AR037230A1 (es) 2004-11-03

Similar Documents

Publication Publication Date Title
NO20040072L (no) Nye substituerte benzimidazol-doseringsformer og fremgangsmate for anvendelse av samme
DK1227088T3 (da) Krystallinsk base af citalopram og hydrochlorid- eller hydrobromidsaltet deraf
NO20031744L (no) Nye ikke-imadazolforbindelser og farmasöytisk preparat omfattende slike
NO20034187D0 (no) Nye spirotricykliske derivater og anvendelse derav som fosfodiesterase-7 inhibitorer
NO20023319L (no) Substituerte glutarimider og deres anvendelse som inhibitorer av IL-12-produksjonen
NO20014135D0 (no) Nye sulfonamidforbindelser og deres anvendelse
DK1429769T3 (da) Nye formuleringer og anvendelse deraf
NO20005266D0 (no) Nye substituerte amider, deres fremstilling og anvendelse
NO20040405L (no) Farmasoytiske sammensetninger av amlodipin og atorvastatin.
NO20040390L (no) Krystallinske former VI og VII av atorvastatinkalsium.
DK1432683T3 (da) Hidtil ukendte krystallinske polymorfe former af lercanidipinhydrochlorid og fremgangsmåder til fremstilling heraf
NO20021786D0 (no) Skumdempningsfremgangsmåter og sammensetninger
NO20033854D0 (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
NO20033797D0 (no) Metode og formel for anti-tumor og anti-metastatisk virkning
NO20052124D0 (no) Nye 1,4-diazabisykloalkanderivater, deres fremstilling og anvendelse
NO20041187L (no) Metoder og blandinger av nye triazinforbindelser
DE60232955D1 (de) Kammförmiges, piezoelektrisches stellglied und herstellungsverfahren dafür
NO20035332D0 (no) Nye heterocykliske derivater og medisinsk anvendelse derav
NO20030843D0 (no) Anordning og fremgangsmåte for kultivering
NO20030822L (no) Nye forbindelser og fremgangsmåter
NO20031928L (no) Nye krystall- og solvatformer av ondansetron-hydroklorid og fremgangmsmåterfor fremstilling derav
NO20035331D0 (no) Nye heterocyklisk forbindelse og medisinsk anvendelse derav
IL153916A0 (en) Solvates of lercanidipine hydrochloride and new crystalline forms of lercanidipine hydrochloride obtained from said solvates
DK1429770T3 (da) Nye formuleringer og anvendelse deraf
ATE285408T1 (de) Paroxetin-n-formyl-derivate

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application